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Irenaeus F De Coo4, Patrick Francis Chinnery2,3 and Thomas Klopstock1,5,6,7*Abstract
Background: Leber’s hereditary optic neuropathy (LHON) is a mitochondrial disease that typically causes bilateral
blindness in young men. Here we describe the clinical and molecular characteristics of 20 patients with disease
onset after the age of 50 years (late onset-LHON).
Methods: From a cohort of 251 affected and 277 unaffected LHON carriers, we identified 20 patients with onset of
visual loss after the age of 50 years. Using structured questionnaires, data including basic demographic details, age of
onset, progression of visual loss and severity as well as exposure to possible environmental triggers including alcohol,
smoking and illicit drugs were retrospectively collected. Groups were compared using the Mann–Whitney-U-Test for
two independent groups of sampled data.
Results: The proportion of late onset-LHON in our cohort was 8% (20 patients, 15 males, 5 females). The mtDNA
mutations m.11778G > A and m.3460G > A were found in 16 and 4 patients, respectively. Among 89 asymptomatic
carriers above the age of 50 years (28 males, 61 females), the mtDNA mutations m.11778G > A, m.3460G > A and
m.14484 T > C were found in 60, 12 and 17 carriers, respectively. Late onset-LHON patients had significantly higher
mean cumulative tobacco and alcohol consumption compared with unaffected carriers. However, there was no
significant difference between late onset- and typical LHON patients with regard to daily tobacco and weekly alcohol
consumption before disease onset.
Conclusion: As already shown for typical LHON, alcohol consumption and smoking are important trigger factors also
for the late manifestation. LHON should be considered in the differential diagnosis of subacute blindness even in older
patients.
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Leber’s hereditary optic neuropathy (LHON) is a mito-
chondrial disease characterized by acute or subacute
visual loss. The vast majority of patients (90%) carry
one of three primary mitochondrial DNA (mtDNA)
mutations: m.11778G >A, m.3460G > A or m.14484 T > C
[1-3]. The prevalence of the disorder has been estimated* Correspondence: Thomas.Klopstock@med.uni-muenchen.de
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article, unless otherwise stated.at about 1 in 30,000 whereas the mutation carrier rate is
estimated to be 1 in 350 [4-6].
LHON is generally perceived as a disease of young
men, reflecting its male preponderance (80%) and its
peak age of onset between the age of 15 and 30 years.
However, cases with late onset of visual loss have been
described [7-16].
Both the incomplete penetrance and the male predomin-
ance in LHON are not fully explained yet. It is considered
as a multifactorial disease with complex interactions
between genetic and environmental factors. In a previous
study, we demonstrated that heavy smoking is a significant
risk factor for disease manifestation [17].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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istics of 20 patients with disease onset after the age of
50 years, and define this group as late onset-LHON.
Subjects and methods
Our study cohort included 251 affected LHON patients
and 277 asymptomatic mutation carriers harbouring one
of the three primary mtDNA mutations (m.11778G > A,
m.3460G > A or m.14484 T > C). Data were available on
demographics, age of onset, progression of visual loss
and severity, mutation type, and possible triggering fac-
tors for visual loss by using a standardized question-
naire). Data on visual function index (VF-14) scores for
402 subjects were also collected, as published previously
[17,18]. From this cohort, we identified 20 patients with
onset of LHON after the age of 50 years and 89 asymp-
tomatic carriers aged >50 years. All subjects were of
white Caucasian origin except one Asian individual.
The respective Institutional Review Boards (Ludwig-
Maximilians-University, Munich, Germany; Newcastle
University, UK; and University Medical Center Rotter-
dam, The Netherlands) approved the study, and in-
formed consent was obtained from each participant.
Data on possible environmental triggers like alcohol,
smoking and illicit drugs were retrospectively collected.
As described in our previous study [17], cumulative
smoking was expressed in terms of ‘pack years’ (PY,
number of cigarettes smoked per day by number of
years smoking), whereas the maximum number of
cigarettes consumed in a single day was defined as
maximum smoking intensity. Similarly, alcohol con-
sumption was expressed in ‘drink years’ (DY, units of
alcohol per week multiplied by the number of years
drinking). Maximum consumption of alcohol was de-
fined as the highest number of units (U) of alcohol
consumed in one week. In line with the previous study




m.11778G > A (%) 167 (66.0) 190 (68.6) 118
m.3460G > A (%) 53 (20.9) 49 (17.7) 31
m.14484 T > C (%) 33 (13.0) 38 (13.7) 29
Total 253 277 178
Sex N, (%)
Male 194 (76.7) 92 (33.2) 134
Female 59 (23.3) 185 (66.8) 45
Male/Female ratio 3.3 0.5 3.0
Mean disease duration 15.9 (16.16) 10.
VF-14 score (SD) 25.1 (20.8) 97.3 (7.1) 25.loss was considered, both for smoking and alcohol con-
sumption of affected individuals.
SPSSTM v.19 statistical software (Chicago, IL, USA) was
used for statistical analysis. The rate of diseased carriers
was calculated performing a lifetime distribution function
F(t) = 1-S(t), were S is the survival function and t time, in-
cluding censored cases. Groups (carriers with late onset-
LHON vs. asymptomatic carriers >50 years old vs. LHON
patients with onset of symptoms before age of 50) were
compared using the Mann–Whitney-U-Test for two inde-
pendent groups of sampled data.
Results
20 out of 253 LHON patients were identified with a dis-
ease onset >50 years (8%). Similar to the complete study
population, the male to female ratio among the affected
20 late onset patients was 3:1 (15 male and 5 female).
The mtDNA mutations m.11778G > A and m.3460G > A
were found in 16 (80%) and 4 (20%) patients, respect-
ively. Among the 277 asymptomatic mutation carriers,
89 were above age 50 (32%), 28 being male and 61 fe-
male. The mtDNA mutations m.11778G > A, m.3460G >
A and m.14484 T > C were found in 60 (67.4%), 12
(13.5%) and 17 (19.1%) of those asymptomatic carriers,
respectively (Table 1). Except for one patient where in-
formation about alcohol and tobacco consumption was
missing, all the other patients consumed alcohol, and 14
out of 19 patients smoked prior to becoming sympto-
matic. Four patients indicated to have had higher than
average stress levels straight before symptoms started
(Table 2).
As already shown in our previous study, the rate of
diseased carriers per age was not influenced by the type
of primary LHON mutation (lifetime distribution func-
tion, log rank p = 0.654). However, the rate of affected
male individuals was significantly higher (lifetime distri-
bution function, log rank p < 0.000).riers <50 Years Carriers ≥50 Years
ected Unaffected Affected Unaffected
(66.3) 78 (66.7) 16 (80) 60 (67.4)
(17.4) 24 (20.5) 4 (20) 12 (13.5)
(16.3) 15 (12.7) 0 (0) 17 (19.1)
117 20 89
(74.9) 32 (27.4) 15 (75.0) 28 (31.5)
(25.1) 85 (72.6) 5 (25.0) 61 (68.5)
0.37 3.0 0.46
71 (10.47) 10.5 (19.12)
14 (21.18) 98.01 (5.22) 18.06 (15.27) 96.45 (8.91)





Tobacco* Alcohol* Other Triggers
1 50 F 11778 + + -
2 50 F 11778 + + -
3 52 M 11778 + + -
4 53 M 11778 + + -
5 53 M 11778 + + +1
6 53 M 11778 + + -
7 53 M 11778 - + +1
8 53 M 11778 + + -
9 55 M 11778 + + -
10 56 M 11778 + + +1
11 56 F 11778 + + -
12 57 M 11778 + + -
13 58 F 3460 - + -
14 61 M 11778 - + -
15 62 M 3460 + + -
16 67 M 11778 - + -
17 74 F 3460 - + -
18 75 M 3460 + + -
19 76 M 11778 + + +1
20 75 M 11778 ? ? ?
*Marked as positive only if consumption was prior to onset of disease.
1Patients indicated increased “stress” as a trigger.
Dimitriadis et al. Orphanet Journal of Rare Diseases 2014, 9:158 Page 3 of 5
http://www.ojrd.com/content/9/1/158There was no significant difference in the mean
duration of disease (time from onset) in patients with
late onset-LHON versus patients with onset <50 years
(8.9+/−9.02 years versus 6.79+/−11.32, p = 0.123). As
expected and in line with our previous study, the mean
VF-14 score for affected patients with late onset-LHON
was significantly lower than that of unaffected carriers overTable 3 Tobacco and alcohol consumption among late onset-
patients
A) Levels of tobacco and alcohol consumption in late onset-LHON patie
Affected N =20
Mean (SD)
Cumulative smoking [PY] 23.36 (27.49)
Maximum smoking consumption [CPD] 19.33 (17.25)
Cumulative alcohol [UY] 137.18 (108.17)
Maximum alcohol consumption [UPW] 99.86 (255.71)
B) Tobacco and alcohol consumption in late onset- vs. “typical” LHON p
Affected N =20 > 50 Y
Daily cigarette consumption [CPD] 13.63 (14.48)
Weekly alcohol consumption [UPW] 27.78 (29.14)
PY = pack years, CPD = cigarettes per day, UY = unit years, UPW = units per week.
3 A) Cumulative and maximum smoking and alcohol consumption in late onset-LHO
and alcohol consumption before disease onset in late onset- as compared to ‘typica50 years old (18.06+/−15.27 versus 96.45+/−8.91, p <
0.000). Comparing the VF-14 scores of late onset-LHON
patients with symptomatic carriers with onset <50 years
showed a trend to lower scores for the older patients
(18.06+/−15.27 versus 25.14+/−21.18, p = 0.144). Within
the late onset-LHON cohort, patients carrying the
m.3460G > A mutation had lower scores than patients
carrying the m.11778 G >A mutation, but the result was
not significant (13.89+/−15.43 versus 19.26+/−15.59,
p = 0.490).
Late onset-LHON patients had significantly higher mean
cumulative tobacco consumption compared with un-
affected carriers above age 50 years (23.4+/−27.5 pack
years (PY), versus 9.3+/−13.9 PY, p = 0.018) and there was
a trend to higher mean maximum intensity of smoking
(19.33+/−17.25 cigarettes per day versus 11.3+/−14.56 cig-
arettes per day, p = 0.059). Concerning alcohol, symptom-
atic carriers had both a significant higher cumulative
consumption and mean maximum intensity of drinking
(137.2+/−108.2 UY versus 62.2+/−87.0 UY, p = 0.012 and
99.86+/−255.71 U/week versus 14.61+/−22.06 U/week,
p < 0.000) (Table 3A).
Expectedly, due to longer exposure, life-time cumula-
tive smoking and alcohol consumption were significantly
higher in late-onset as compared to typical LHON pa-
tients (23.4+/−27.5 pack years (PY), versus 4.9+/−8.01
PY, p < 0.000; 137.2+/−108.2 UY versus 33.3+/−56.0 UY,
p = 0.001). However, there was no significant difference
with regard to daily tobacco and weekly alcohol con-
sumption before disease onset (13.6+/−14.5 cigarettes/
day versus 10.3+/−10.4 cigarettes/day, p = 0.619 and 27.8
+/−29.1 U/week versus 18.1+/− 19.5 U/week, p = 0.284)
(Table 3B). This was also true when the analysis was re-
stricted to the 14 late-onset LHON and 89 typical
LHON cases that had exposure to both alcohol and to-
bacco (data not shown).LHON patients, unaffected carriers and “typical” LHON
nts vs. unaffected carriers over 50 years old







ears Affected N =178 < 50 Years
10.03 (10.43) 0.619
18.09 (19.47) 0.284
N patients as compared to unaffected carriers over 50 years B) daily cigarette
l’ LHON patients.
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Although most affected individuals with LHON lose
vision in the second or third decade of life, the disease
is not restricted to young adults. Here we describe a
cohort of patients with onset after the age of 50 years
(late onset-LHON). Late onset occurred in 20 of 251
LHON patients in our cohort, corresponding to 8% of
patients. While all previously reported cases of late
onset in LHON were males, the sex ratio in our study
is similar to typical disease in young adults with a
male to female ratio of about 3:1. Likewise, we found
no difference between typical and late-onset LHON in
the distribution of the causative mtDNA mutations
and in the severity of the disease as measured using
the VF-14 index.
The triggering factors for visual loss in patients har-
boring one of the typical mutations for LHON are not
fully known. Apart from alcohol and smoking, for which
a correlation was recently demonstrated [17], many
other triggers have been described in single case reports,
such as lack of oestrogens, trauma, antiretroviral ther-
apy, HIV, anaemia, cyanide and carbon monoxide intoxi-
cation [9,19-23].
Recent studies provided some molecular evidence that
estrogens activate the antioxidant enzyme superoxide
dismutase 2 and also the mitochondrial biogenesis and
thus play a role in maintaining vision in female LHON
carriers [24]. In one female with a 11778G > A mutation
the natural absence of estrogens at a young age (because
of a Perrault syndrome) is discussed as a possible reason
for the severe optic atrophy with early onset [25]. While
our data do not allow for conclusions on protective ef-
fects of estrogens, the similar male/female ratios both in
late onset vs. typical LHON patients and in unaffected
mutation carriers above vs. below age 50 years argue
clearly against post-menopause as a manifestation factor
of the disease.
As already shown for typical LHON, alcohol consump-
tion and smoking are important risk factors for disease
conversion among patients with late onset-LHON. In the
literature, there was one 67-year-old patient who lost his
vision after blood loss due to hemorrhage from multiple
small bowel arteriovenous malformations and a second
one with a long history of HIV and zidovudine treatment
prior to onset of disease [9,19]. Recently a case series of
three late onset-LHON patients with raised intraocular
pressure as a potential risk factor triggering visual loss
were described [26]. Besides alcohol consumption and
smoking, no other secondary factors influencing disease
expression were elucidated in late-onset LHON patients
reported in this study or in the literature. The finding that
life-time cumulative smoking and alcohol consumption
are significantly higher in late-onset as compared to youn-
ger LHON patients is rather self-evident and does notprovide any explanation for the later disease manifestation.
More interestingly, the daily tobacco and weekly alcohol
consumption before disease onset were not significantly
different between late-onset and typical LHON patients.
The fact that these pre-manifestation exposure rates to al-
cohol and tobacco as well as mutation profile and gender
distribution are very similar in late onset-LHON and in
the younger cases indicates that environmental factors are
only partly explaining the variable penetrance of the
disease.
Conclusion
In conclusion, alcohol consumption and smoking are
important trigger factors not only for typical LHON but
also for late-onset LHON. Moreover, this study shows
that LHON should be considered in the differential
diagnosis of subacute blindness even in older patients.
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